Obstetrics and gynecology · 2009
Irinotecan use during pregnancy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taylor Justin, Amanze Adanna, Di Federico Elaine, Verschraegen Claire
Аннотация
BACKGROUND: Ovarian tumors during pregnancy are rare. There is sparse clinical evidence about the safety of chemotherapy in this situation.
CASE: A 34-year-old woman was diagnosed by ultrasonography at 15 1/2 weeks of pregnancy with a Krukenberg tumor. She was treated with surgical removal and 10 courses of the combination of 5-fluorouracil, folinic acid, and irinotecan every 2 weeks until the 36th week of her pregnancy. The neonate was born without complications, and at age 4 months, showed normal development and no teratogenic effects.
CONCLUSION: In this case, irinotecan started at the second trimester and was safely used at full adjuvant dose.
CASE: A 34-year-old woman was diagnosed by ultrasonography at 15 1/2 weeks of pregnancy with a Krukenberg tumor. She was treated with surgical removal and 10 courses of the combination of 5-fluorouracil, folinic acid, and irinotecan every 2 weeks until the 36th week of her pregnancy. The neonate was born without complications, and at age 4 months, showed normal development and no teratogenic effects.
CONCLUSION: In this case, irinotecan started at the second trimester and was safely used at full adjuvant dose.